Integrative Multi-Model Analysis Identifies a Core Gene Signature Associated with WEE1 Inhibitor Resistance, the Resistance-Associated Tumor Microenvironment, and Therapeutic Vulnerability in Ovarian Cancer.
BACKGROUND Ovarian cancer is the most lethal gynecological malignancy, and acquired resistance to chemotherapy and targeted therapy is a central cause of treatment failure. The WEE1 inhibitor AZD1775 (adavosertib) has shown clinical activity in ovarian cancer, particularly in tumors with TP53 dysfunction, but acquired...